Literature DB >> 22565311

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.

Daofeng Liu1, Liping Song, Jie Wei, Amy N Courtney, Xiuhua Gao, Ekaterina Marinova, Linjie Guo, Andras Heczey, Shahab Asgharzadeh, Eugene Kim, Gianpietro Dotti, Leonid S Metelitsa.   

Abstract

Vα24-invariant NKT cells inhibit tumor growth by targeting tumor-associated macrophages (TAMs). Tumor progression therefore requires that TAMs evade NKT cell activity through yet-unknown mechanisms. Here we report that a subset of cells in neuroblastoma (NB) cell lines and primary tumors expresses membrane-bound TNF-α (mbTNF-α). These proinflammatory tumor cells induced production of the chemokine CCL20 from TAMs via activation of the NF-κB signaling pathway, an effect that was amplified in hypoxia. Flow cytometry analyses of human primary NB tumors revealed selective accumulation of CCL20 in TAMs. Neutralization of the chemokine inhibited in vitro migration of NKT cells toward tumor-conditioned hypoxic monocytes and localization of NKT cells to NB grafts in mice. We also found that hypoxia impaired NKT cell viability and function. Thus, CCL20-producing TAMs served as a hypoxic trap for tumor-infiltrating NKT cells. IL-15 protected antigen-activated NKT cells from hypoxia, and transgenic expression of IL-15 in adoptively transferred NKT cells dramatically enhanced their antimetastatic activity in mice. Thus, tumor-induced chemokine production in hypoxic TAMs and consequent chemoattraction and inhibition of NKT cells represents a mechanism of immune escape that can be reversed by adoptive immunotherapy with IL-15-transduced NKT cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565311      PMCID: PMC3366399          DOI: 10.1172/JCI59535

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.

Authors:  Liping Song; Tasnim Ara; Hong-Wei Wu; Chan-Wook Woo; C Patrick Reynolds; Robert C Seeger; Yves A DeClerck; Carol J Thiele; Richard Sposto; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 2.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.

Authors:  Paola Allavena; Antonio Sica; Graziella Solinas; Chiara Porta; Alberto Mantovani
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-29       Impact factor: 6.312

3.  NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.

Authors:  Kori L Wallace; Melissa A Marshall; Susan I Ramos; Joanne A Lannigan; Joshua J Field; Robert M Strieter; Joel Linden
Journal:  Blood       Date:  2009-05-11       Impact factor: 22.113

4.  Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept.

Authors:  Jonathan Friedberg; Eric Jacobsen; Donna Neuberg; Jeffrey Kutok; Olivier Munoz; Vassiliki Boussiotis; Hazel Reynolds; David Fisher; Agnieszka Szot; Annick Van Den Abbeele; Arnold Freedman
Journal:  Leuk Lymphoma       Date:  2008-05

5.  Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.

Authors:  Siok-Keen Tey; Gianpietro Dotti; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Biol Blood Marrow Transplant       Date:  2007-05-29       Impact factor: 5.742

Review 6.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

7.  Expanded CD34+ human umbilical cord blood cells generate multiple lymphohematopoietic lineages in NOD-scid IL2rgamma(null) mice.

Authors:  Lisa J Giassi; Todd Pearson; Leonard D Shultz; Joseph Laning; Kristin Biber; Morey Kraus; Bruce A Woda; Madelyn R Schmidt; Robert T Woodland; Aldo A Rossini; Dale L Greiner
Journal:  Exp Biol Med (Maywood)       Date:  2008-08

8.  Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

Authors:  Concetta Quintarelli; Juan F Vera; Barbara Savoldo; Greta M P Giordano Attianese; Martin Pule; Aaron E Foster; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2007-07-17       Impact factor: 22.113

9.  A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.

Authors:  E R Brown; K A Charles; S A Hoare; R L Rye; D I Jodrell; R E Aird; R Vora; U Prabhakar; M Nakada; R E Corringham; M DeWitte; C Sturgeon; D Propper; F R Balkwill; J F Smyth
Journal:  Ann Oncol       Date:  2008-03-05       Impact factor: 32.976

10.  Hypoxia transcriptionally induces macrophage-inflammatory protein-3alpha/CCL-20 in primary human mononuclear phagocytes through nuclear factor (NF)-kappaB.

Authors:  Florinda Battaglia; Silvana Delfino; Elisa Merello; Maura Puppo; Roberto Piva; Luigi Varesio; Maria Carla Bosco
Journal:  J Leukoc Biol       Date:  2007-12-18       Impact factor: 4.962

View more
  65 in total

Review 1.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

2.  Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia.

Authors:  James S Brown
Journal:  Schizophr Bull       Date:  2016-05-11       Impact factor: 9.306

3.  Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32.

Authors:  Markus Maeurer; Martin Rao; Alimuddin Zumla
Journal:  Ann Transl Med       Date:  2015-05

Review 4.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

5.  Tumor-infiltrating lymphocytes (TILs) from patients with glioma.

Authors:  Zhenjiang Liu; Qingda Meng; Jiri Bartek; Thomas Poiret; Oscar Persson; Lalit Rane; Elena Rangelova; Christopher Illies; Inti Harvey Peredo; Xiaohua Luo; Martin Vijayakumar Rao; Rebecca Axelsson Robertson; Ernest Dodoo; Markus Maeurer
Journal:  Oncoimmunology       Date:  2016-11-29       Impact factor: 8.110

6.  NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma.

Authors:  Xin Xu; Wei Huang; Andras Heczey; Daofeng Liu; Linjie Guo; Michael Wood; Jingling Jin; Amy N Courtney; Bin Liu; Erica J Di Pierro; John Hicks; Gabriel A Barragan; Ho Ngai; Yuhui Chen; Barbara Savoldo; Gianpietro Dotti; Leonid S Metelitsa
Journal:  Clin Cancer Res       Date:  2019-09-04       Impact factor: 12.531

Review 7.  The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Cancer Immunol Immunother       Date:  2014-01-03       Impact factor: 6.968

8.  Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.

Authors:  Janine L Oliver; Matthew P Alexander; Allison G Norrod; Irene M Mullins; David W Mullins
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-11       Impact factor: 4.693

Review 9.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

10.  RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.

Authors:  Fernanda Pohl-Guimarães; Changlin Yang; Kyle A Dyson; Tyler J Wildes; Jeffrey Drake; Jianping Huang; Catherine Flores; Elias J Sayour; Duane A Mitchell
Journal:  Mol Ther       Date:  2018-10-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.